CN107348522A - A kind of alimentation composition for improving the elderly's kinematic system function and preparation method thereof - Google Patents
A kind of alimentation composition for improving the elderly's kinematic system function and preparation method thereof Download PDFInfo
- Publication number
- CN107348522A CN107348522A CN201710693890.2A CN201710693890A CN107348522A CN 107348522 A CN107348522 A CN 107348522A CN 201710693890 A CN201710693890 A CN 201710693890A CN 107348522 A CN107348522 A CN 107348522A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- elderly
- kinematic system
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 89
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 50
- 210000000845 cartilage Anatomy 0.000 claims abstract description 30
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 30
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 29
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000011575 calcium Substances 0.000 claims abstract description 26
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 26
- 235000018102 proteins Nutrition 0.000 claims abstract description 25
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 25
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 25
- 229940088594 vitamin Drugs 0.000 claims abstract description 23
- 229930003231 vitamin Natural products 0.000 claims abstract description 23
- 235000013343 vitamin Nutrition 0.000 claims abstract description 23
- 239000011782 vitamin Substances 0.000 claims abstract description 23
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 23
- 102000008186 Collagen Human genes 0.000 claims abstract description 22
- 108010035532 Collagen Proteins 0.000 claims abstract description 22
- 102000004407 Lactalbumin Human genes 0.000 claims abstract description 21
- 108090000942 Lactalbumin Proteins 0.000 claims abstract description 21
- 229920001436 collagen Polymers 0.000 claims abstract description 21
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 20
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 20
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000011777 magnesium Substances 0.000 claims abstract description 18
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 18
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 16
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 16
- 241000209140 Triticum Species 0.000 claims abstract description 16
- 235000021307 Triticum Nutrition 0.000 claims abstract description 16
- 235000021119 whey protein Nutrition 0.000 claims abstract description 16
- 235000012754 curcumin Nutrition 0.000 claims abstract description 15
- 239000004148 curcumin Substances 0.000 claims abstract description 15
- 229940109262 curcumin Drugs 0.000 claims abstract description 15
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 15
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 14
- 230000036541 health Effects 0.000 claims abstract description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 34
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 34
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 claims description 25
- 229930003316 Vitamin D Natural products 0.000 claims description 23
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 23
- 235000019166 vitamin D Nutrition 0.000 claims description 23
- 239000011710 vitamin D Substances 0.000 claims description 23
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 23
- 229940046008 vitamin d Drugs 0.000 claims description 23
- 235000019154 vitamin C Nutrition 0.000 claims description 18
- 239000011718 vitamin C Substances 0.000 claims description 18
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 17
- 229930003268 Vitamin C Natural products 0.000 claims description 17
- 229930003427 Vitamin E Natural products 0.000 claims description 17
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 17
- 235000019165 vitamin E Nutrition 0.000 claims description 17
- 229940046009 vitamin E Drugs 0.000 claims description 17
- 239000011709 vitamin E Substances 0.000 claims description 17
- 235000019156 vitamin B Nutrition 0.000 claims description 16
- 239000011720 vitamin B Substances 0.000 claims description 16
- 229940046001 vitamin b complex Drugs 0.000 claims description 16
- 239000011728 vitamin K2 Substances 0.000 claims description 15
- 230000006872 improvement Effects 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 12
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 claims description 10
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 8
- 102000002322 Egg Proteins Human genes 0.000 claims description 8
- 108010000912 Egg Proteins Proteins 0.000 claims description 8
- 235000014103 egg white Nutrition 0.000 claims description 8
- 210000000969 egg white Anatomy 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- 235000016709 nutrition Nutrition 0.000 abstract description 14
- 239000004615 ingredient Substances 0.000 abstract description 7
- 239000013589 supplement Substances 0.000 abstract description 6
- 235000015097 nutrients Nutrition 0.000 abstract description 5
- -1 hydroxyl β methylbutanoic acids Chemical class 0.000 abstract description 2
- 210000000988 bone and bone Anatomy 0.000 description 53
- 230000006870 function Effects 0.000 description 40
- 210000003205 muscle Anatomy 0.000 description 36
- 230000000052 comparative effect Effects 0.000 description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 239000000047 product Substances 0.000 description 22
- 208000001132 Osteoporosis Diseases 0.000 description 19
- 230000037182 bone density Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 230000002354 daily effect Effects 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 11
- 210000001188 articular cartilage Anatomy 0.000 description 11
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 11
- 238000003304 gavage Methods 0.000 description 11
- 229960002442 glucosamine Drugs 0.000 description 11
- 210000002027 skeletal muscle Anatomy 0.000 description 10
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 9
- 244000068988 Glycine max Species 0.000 description 9
- 235000010469 Glycine max Nutrition 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 102000002734 Collagen Type VI Human genes 0.000 description 8
- 108010043741 Collagen Type VI Proteins 0.000 description 8
- 230000007850 degeneration Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000035764 nutrition Effects 0.000 description 7
- 201000008482 osteoarthritis Diseases 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 210000001503 joint Anatomy 0.000 description 6
- 210000003127 knee Anatomy 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 229920001287 Chondroitin sulfate Polymers 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229940059329 chondroitin sulfate Drugs 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 241001421185 Anomis Species 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 239000005862 Whey Substances 0.000 description 4
- 210000002805 bone matrix Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000003387 muscular Effects 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 244000163122 Curcuma domestica Species 0.000 description 3
- 235000003392 Curcuma domestica Nutrition 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010057178 Osteoarthropathies Diseases 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000037118 bone strength Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000007910 chewable tablet Substances 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000003373 curcuma longa Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 239000006101 laboratory sample Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 230000004118 muscle contraction Effects 0.000 description 3
- 230000037257 muscle growth Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- 229910052717 sulfur Chemical group 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 235000013976 turmeric Nutrition 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010007710 Cartilage injury Diseases 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000055008 Matrilin Proteins Human genes 0.000 description 2
- 108010072582 Matrilin Proteins Proteins 0.000 description 2
- 208000006735 Periostitis Diseases 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000008468 bone growth Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 230000004220 muscle function Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 210000003460 periosteum Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000012805 post-processing Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- JCZPMGDSEAFWDY-SQOUGZDYSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide Chemical compound NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO JCZPMGDSEAFWDY-SQOUGZDYSA-N 0.000 description 1
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 description 1
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 description 1
- PFRQBZFETXBLTP-RCIYGOBDSA-N 2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]-3-methyl-1,4-dihydronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-RCIYGOBDSA-N 0.000 description 1
- 108010046716 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) Proteins 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 102000016284 Aggrecans Human genes 0.000 description 1
- 108010067219 Aggrecans Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 102000040350 B family Human genes 0.000 description 1
- 108091072128 B family Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical group OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- 101710159002 L-lactate oxidase Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 108020002496 Lysophospholipase Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 description 1
- 101001005952 Rattus norvegicus H-2 class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 208000026214 Skeletal muscle atrophy Diseases 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000014701 Transketolase Human genes 0.000 description 1
- 108010043652 Transketolase Proteins 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 210000000459 calcaneus Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910001576 calcium mineral Inorganic materials 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000025185 skeletal muscle atrophy Effects 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 102000009310 vitamin D receptors Human genes 0.000 description 1
- 108050000156 vitamin D receptors Proteins 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940010250 vitamin k 2 Drugs 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides a kind of alimentation composition for improving the elderly's kinematic system function and preparation method and application, and the alimentation composition is made up of following composition by weight：10 15 parts of lactalbumin, 0.5 1 parts of whey protein peptide, 0.5 1 parts of wheat protein peptide, 2 10 parts of collagen peptide, 0.05 0.15 parts of CPP, 25 parts of leucine, 0.5 3 parts of β hydroxyl β methylbutanoic acids, 0.5 1 parts of calcium, 0.2 0.5 parts of magnesium, 5 20 parts of chick sternal cartilage, 0.1 0.5 parts of chitosan oligosaccharide, 0.5 2 parts of dimethyl sulfone, 0.1 1 parts of curcumin, 0.02 0.15 parts of vitamin mixtures.The present invention realizes required nutritional ingredient based on the theoretical thought of system trophism, specific aim supplement the elderly's kinematic system functional status.Promote to realize the holistic health of the elderly's kinematic system by the function collaboration of each nutrient.
Description
Technical field
The present invention relates to a kind of alimentation composition for improving the elderly's kinematic system function and preparation method and application.
Background technology
The aging speed in the whole world is constantly accelerated.The predictive display of the United Nations's issue, more than the 60 years old proportion of aged population in the world
10.0% is accounted within 2000, will rise within 2025 15.1%, this ratio will be up to 21.7% during the year two thousand fifty.With the age
Growth, the physiological function of the kinematic system of human body is in the state progressively degenerated, and most of the elderly has osteoporosis, moved back
The problem of row osteoarthropathy (articular cartilage degeneration) and skeletal muscle are reduced, its final result often drops the mobility of the elderly
It is low, walking, sitting, ascend a height and to put forward the everyday actions such as weight impacted, even result in disequilibrium, be difficult to stand, easily fall down
Deng.
Kinematic system is made up of three kinds of bone, bony union (joint) and skeletal muscle organs.Bone with different joints (it is inactive, half
Activity or activity) link together, form bone.The grown form of human body is formd, and attachment is provided for muscle, is propped up in nerve
Under matching somebody with somebody, contraction of muscle, the bone accompanying by it is pulled, using movable bony union as hinge, produce lever motion.From movement angle
See, bone is passive part, and skeletal muscle is power section, and joint is the hinge of motion.In fact, muscle, bone, Bones and joints three
Person's tight association in motor function, mutually regulation and control also be present.
According to muscle, bone and osteoporosis Consensus of experts, osteoporosis and muscle, bone are closely related.Osteoporosis
There is many common risk factors for disease and the few disease of flesh.Muscle, bone belong to kinematic system together, originating from mesoderm, have
Common mesenchymal precursor, both tight associations in motor function.Muscle is the tie that bone is connected with bone, growth and hair with bone
Educate closely related.Recent studies have found that muscle and bone are important endocrine organs, the correlation factor of muscle secretion participates in
The regulation and control of bone, growth, development, development to bone have a certain impact, and the equally adjustable flesh amount of bone factor, muscular strength.Hair
Educate biological study prompting and there may be and coordinate flesh, the molecular signal network of bone mass, circulating and existing in local microenvironment
The regulatory factor of muscle and bone growth can be coupled.Muscle and bone except simultaneously by internal (neuroendocrine) and outside (power) because
Outside element influences, mutually regulation and control also be present.
Development, function and the aging of skeletal musculature are an organic wholes.Muscle under nervous system regulation and control is received
The strength of contracting is an important factor for determining bone amount, bone strength.Influence of the muscular strength to bone density, the shadow than Lean mass to bone density
Sound is more notable.Skeletal muscle quantity is an important factor for determining bone density.Muscle quantity is in synchronous increase and decrease with bone density.Bone
Flesh, which is lost, to cause bone density to decline.Muscular atrophy, muscular strength decline and muscle function decline can cause cortex bone information to accelerate, become
It is thin, anti-shearing force, torsion and bending power ability are died down；Horizontal bone trabecula quantity in cancellous bone is reduced, and vertical bone trabecula becomes
Must be sparse, bone density is more and more lower.Bone can adapt to the change of contraction of muscle strength by changing bone amount and bone strength.Bone
The mechanical stimulation born has a major impact to bone density.Mechanical stimulation is converted to biochemical signals regulation bone density by osteocyte.
Bone density declines the result of exactly musculoskeletal system Imbalance.
Degenerative osteoarthropathy is also referred to as Osteoarthritis, is a kind of retrogression pathological changes, be due to increase age, obesity, strain,
Under articular cartilage degeneration damage, joint margins and the cartilage caused by factors such as wound, joint birth defect, joint deformity
Bone reactive hyperplasia.Dystrophia occurs for studies have shown that cartilage, and cartilage matrix degraded exceedes synthesis, and it is to make that repair ability, which reduces,
The main reason for into degenerative joint disease.The result of study of gonitis is shown, knee joint skeletal muscle exists weak and feeble
(skeletal muscle atrophy, muscular strength decline), which is that one of gonitis is important, wants pathology link, it is generally recognized that is drawn by arthritis ache
Caused by the muscle suppression risen and secondary atrophy.And there have research to think that the quadriceps muscle of thigh for increasing age correlation withers to be weak in knee osteoarthritis
Path on play an important role.
And be that part is intervened respectively mostly the intervention of nutrition and field of food to kinematic system, examined without systematic entirety
Consider.As individually supplement calcium and/or vitamin D to improve osteoporosis, individually supplement the compositions such as Glucosamine and closed with alleviating
Save cartilage degradation.And ignored more than the loss for skeletal muscle by masses.
Osteoporosis, degenerative osteoarthropathy (articular cartilage degeneration) and skeletal muscle be present simultaneously in general most of the elderly
The problem of reduction, the vitamin D for whether improving osteoporosis adds calcium tablet, or alleviates the Glucosamine that joint is returned,
Can not be overall improvement kinematic system the problem of, effect is single, is not preferable product.
The content of the invention
It is an object of the present invention to provide a kind of alimentation composition for improving the elderly's kinematic system function and its preparation side
Method and application, improve old human body kinematic system function in terms of muscle, bone, Bones and joints three.
To achieve these goals, the present invention adopts the following technical scheme that：
A kind of alimentation composition for improving the elderly's kinematic system function, is made up of following composition by weight：Whey egg
White 10-15 parts, whey protein peptide 0.5-1 parts, wheat protein peptide 0.5-1 parts, collagen peptide 2-10 parts, CPP
0.05-0.15 parts, leucine 2-5 parts, beta-hydroxy-Beta-methyl butyric acid 0.5-3 parts, calcium 0.5-1 parts, magnesium 0.2-0.5 parts, pigeon breast
Gartilage powder 5-20 parts, chitosan oligosaccharide 0.1-0.5 parts, dimethyl sulfone 0.5-2 parts, curcumin 0.1-1 parts, vitamin mixtures 0.8-
1.2 part.
Preferably, the alimentation composition for improving the elderly's kinematic system function, is made up of following composition by weight：
Lactalbumin 12-15 parts, whey protein peptide 0.5-0.8 parts, wheat protein peptide 0.5-0.8 parts, collagen peptide 3-10 parts, junket egg
White phosphoeptide 0.05-0.1 parts, leucine 2-4 parts, beta-hydroxy-Beta-methyl butyric acid 1-3 parts, calcium 0.5-0.8 parts, magnesium 0.2-0.4
Part, chick sternal cartilage 10-20 parts, chitosan oligosaccharide 0.2-0.5 parts, dimethyl sulfone 1-2 parts, curcumin 0.5-1 parts, vitamin mixtures
0.9-1.1 parts.
It is further preferred that it is described improve the elderly's kinematic system function alimentation composition, by it is following by weight into
It is grouped into：Lactalbumin 14-15 parts, whey protein peptide 0.6-0.7 parts, wheat protein peptide 0.6-0.7 parts, collagen peptide 5-10
Part, CPP 0.05-0.8 parts, leucine 3-4 parts, beta-hydroxy-Beta-methyl butyric acid 2-3 parts, calcium 0.5-0.6 parts, magnesium
0.2-0.3 parts, chick sternal cartilage 15-20 parts, chitosan oligosaccharide 0.3-0.5 parts, dimethyl sulfone 1.5-2 parts, curcumin 0.5-0.8 parts,
Vitamin mixtures 0.9-1.0 parts.
Further, the vitamin mixtures contain vitamin B complex, vitamin D, vitamin C, vitamin E, vitamin
K2；Also contain the available carrier in appropriate this area.
Further, the content of each vitamin is in vitamin mixtures described in every 1g：Vitamin B complex 12-42mg, dimension
Raw plain D 3-10 μ g, vitamin C 30-100mg, vitamin E 5-15mg, vitamin K2 70-90μg。
Yet further, the content of each vitamin is in vitamin mixtures described in every 1g：Vitamin B complex 20-42mg, dimension
Raw plain D5-10 μ g, vitamin C 50-100mg, vitamin E 10-15mg, vitamin K2 80-90μg。
It is preferred that the content of each vitamin is in vitamin mixtures described in per 1g：Vitamin B complex 42mg, vitamin D 8
μ g, vitamin C 100mg, vitamin E 14mg, vitamin K2 90μg。
Calcium of the present invention can be provided by the calcium mineral such as calcium monohydrogen phosphate, calcium carbonate matter；The magnesium can contain magnesium by magnesium sulfate
Mineral matter provides.
Each raw material of the present invention is commercially available.
The present invention also provides the preparation method of the alimentation composition of above-mentioned improvement the elderly kinematic system function, can be by ability
Domain conventional method takes each raw material, mixing by proportioning.Usually, the method that " equal increments " can be used, mixed with three-dimensional " V " type
Material machine, 5~10min of mixing or so, you can be well mixed above-mentioned raw materials.
The recommendation dose of the alimentation composition of the present invention for improving the elderly's kinematic system function is 35-50g/ days.
Typically continuously take to obtain for 30-60 days and significantly improve.
The present invention also provides the preparation of the alimentation composition containing above-mentioned improvement the elderly kinematic system function.
Further, the preparation is also containing auxiliary material and/or additive used in field of food, field of health care food；Or
The preparation is also containing pharmaceutically available carrier.
In the production of the preparation can according to the general knowledge of those skilled in the art add field of food, field of health care food or
Pharmaceutically conventional auxiliary material, additive, carrier etc., such as carrier, excipient, diluent, disintegrant, aromatic, colouring agent, sweet tea
Taste agent etc., the microcrystalline cellulose that can be such as used as excipient and/or disintegrant.
The preparation can be the various regular dosage forms in this area, such as tablet (containing chewable tablets), capsule, granule, tabletting
Candy, powder etc..Such as can be directly filling in glue by the alimentation composition of the above-mentioned improvement the elderly kinematic system function of the present invention
Capsule is made in capsule；Or after drying of being pelletized, it is tabletted with tablet press machine.
The alimentation composition and its preparation of the above-mentioned improvement the elderly kinematic system function of the present invention can be eaten directly as terminal
Product, also can be as the dispensing of food or health food.
Present invention additionally comprises the alimentation composition of above-mentioned improvement the elderly kinematic system function or its preparation to prepare food
Or the application in health products or medicine.
Compared with prior art, the present invention has the advantages that：
In terms of muscle decay is improved：
(1) by the combination of whole albumen (lactalbumin) and protein hydrolysate (whey protein peptide, collagen peptide), egg is formed
The Gradient Absorption of white matter, energy and raw material are persistently provided for muscle；
(2) lactalbumin contains higher leucine, at the same be supplemented part leucine and its metabolite beta-hydroxy-β-
Methylbutanoic acid, it is most strong that leucine promotes protein level of skeletal muscle to synthesize, and beta-hydroxy-Beta-methyl butyric acid helps to promote flesh to greatest extent
The increase of human body product, cooperates with other nutriments that the decline of the elderly's muscle quality and function can be reversed；
(3) vitamin B complex participates in energetic supersession, can further adjust muscle energy supply.The supply of energy is muscle strength
Important sources.The vitamin that energetic supersession is participated in coenzyme or prothetic group is mainly B family vitamin, mainly including VB1, VB2, VB6.
VB1 activity form forms the coenzyme of alpha-ketoacid dehydrogenase system and transketolase in vivo, is primarily involved in sugar and branched-amino
The metabolism of acid.VB2 is combined with FMN, the nucleic acid co-enzyme form of flavin adenine two with specific protein in vivo, extensively
The general redox reaction participated in metabolism.Because the nucleic acid of flavin adenine two is the part of respiratory chain, therefore, VB2
It is the key link of energy production.VB6 is used as many enzymes (such as transaminase, decarboxylation using its active form, pyridoxal 5 '-phosphate
Enzyme) coenzyme participate in amino acid metabolism.
(4) vitamin D is added to increase muscle strength and function.The function of vitamin D passes through following two approach：One side
Face, vitamin D make mRNA expression increase, promote flesh by being combined with the vitamin D receptor of Skeletal Muscle Cell surface specific
Fiber synthesizes.On the other hand, vitamin D can make sarcoplasmic reticulum storage calcium increase, promote contraction of muscle function.
(5) wheat protein peptide contains abundant glutamine, and glutamine is metabolic consumption under human body stress situation
Most amino acid, and the most amino acid of content in human skeletal muscle, muscle cell volume can be increased, suppress albumen point
Solution, while glutamine can adjust the elderly's gut barrier function and immunity, promote the absorption of nutritional ingredient；
(6) response to oxidative stress of muscle is reduced by vitamin C of the supplement with antioxidation, vitamin E.Mitigate
The damage that oxidative stress comes to bands of muscle, safeguards muscle function.
In terms of osteoporosis is improved：
(1) the main composition calcium and collagen (peptide) of bone are supplemented.97%-98% is bone matrix in bone tissue,
65% dimension mineral matter in bone matrix, 35% is organic substance, and 95% is collagen in organic substance.Supplement calcium and collagen
Contribute to the intensity and toughness of increase bone, so as to improve osteoporosis；
(2) replenishing vitamins K2.Farnoquinone plays the role of important in multiple links of Bone m etabolism, there is promoting bone growing
With the two-way function for suppressing bone information, the imbalance state of metabolism of bone tissue can be improved, improve bone mass, so as to increase bone strength.
(3) CPP and vitamin D are supplemented.CPP can promote absorption of the small intestine to calcium.Vitamin D
Absorption of the enteron aisle to calcium and phosphorus can be promoted, Gegenbaur's cell can be stimulated to promote osteoid tissue maturation and bone mineralization.
(4) replenishing vitamins C, the regeneration of bone collagen is promoted.During collagen synthesis, proline in its polypeptide chain and
The residues such as lysine must first hydroxylation be hydroxyproline and hydroxyl respectively under the catalysis of proline carboxylase and lysyl hydroxylase
The residues such as lysine.Vitamin C is one of cofactor necessary to these hydroxylases maintain activity.
(5) magnesium is supplemented.Element necessary to magnesium is osteocyte 26S Proteasome Structure and Function, makes bone growth and maintenance, and magnesium can influence
The absorption of bone.
In terms of articular cartilage damage is improved：
(1) chick sternal cartilage contains the important structure of the Bones and joints such as abundant collagen, Glucosamine, chondroitin sulfate
Into composition, simultaneously containing the various active factor such as basic fibroblast growth factor, IGF, can promote soft
Bone cell growth, bone matrix synthesis is accelerated to promote the reparation of articular cartilage and slow down articular cartilage degeneration；
(2) dimethyl sulfone is the master of sulphur in human body synthetic methionine, cystine and sulfur-bearing peptide, albumen, and sulfur-bearing tissue
Want one of source of supply.The mucous membrane of joint junction containing sulfoprotein and gucosamine etc. by forming.The albumen and glucose of sulfur-bearing
Amine etc. has the generation for promoting collagen, increases the combination of water, helps to repair the function of damaged cartilage.Injured cartilage can be made extensive
Multiple normal, periosteum liquid is denseer, more toughness, so as to strengthen the defencive function of periosteum, mitigates the friction of Bones and joints, reduces pain.
(3) chitosan oligosaccharide is the oligosaccharide being formed by connecting by 2-10 aminoglucose by β-Isosorbide-5-Nitrae glycosidic bond, can promote to slide
Film, repair of cartilage, the Mediators of inflammation in knuckle synovia is reduced, be effectively improved the symptom of osteoarthritis.
(4) curcumin, turmeric are also traditional blood circulation and stasis-eliminating medicine, can blood-activating and qi-promoting analgesic.Saving cortilage cartilage suppresses bone
Arthritic effect is mainly realized by following aspect：Curcumin can be removed free radical, complete anti-by suppressing oxidation enzyme
Oxidation, so as to prevent the generation of osteoarthritis and progress；Curcumin suppress matrix metalloproteinase to cartilage matrix
Consumption, increase the generation of II Collagen Type VI；Curcumin is by suppressing cytosolic phospholipase A2, cyclooxygenase 2, LOX 5, so as to
Complete anti-inflammatory response.
The present invention is based on the theoretical thought of system trophism, overall in terms of bone, joint, muscle three to consider, specific aim
Supplement the nutritional ingredient required for the elderly's kinematic system functional status is realized.By the function of each nutrient, and its it
Between level it is progressive, scientific matching, collaboration promotes to realize the holistic health of the elderly's kinematic system, daily so as to improve the elderly
Mobility and quality of life.
Composition provided by the invention can improve osteoporosis from the catabolism for promoting muscle growth, reducing muscle,
Many-sided function to human motion system such as reparation of articular cartilage is promoted to improve, to improve the elderly's mobility.
Simultaneously, moreover it is possible to effectively remove the accumulation of interior free yl, reduce the effect of vivo oxidation stress reaction, make body more healthy.
Embodiment
Following examples are used to illustrate the present invention, but are not limited to the scope of the present invention.It is unreceipted specific in embodiment
Technology or condition person, carried out according to the technology or condition described by document in the art, or according to product description.It is used
Reagent or the unreceipted production firm person of instrument, it is the conventional products that can be commercially available by regular distributor.
Embodiment 1
A kind of alimentation composition for improving the elderly's kinematic system function, is made up of following composition by weight：Whey egg
White 15g, whey protein peptide 0.7g, wheat protein peptide 0.7g, collagen peptide 10g, CPP 0.2g, leucine 4g,
Beta-hydroxy-Beta-methyl butyric acid 3g, calcium 0.5g, magnesium 0.2g, chick sternal cartilage 10g, chitosan oligosaccharide 0.3g, dimethyl sulfone 1.5g, turmeric
Plain 0.5g, vitamin B complex 42mg, μ g of vitamin D 8, vitamin C 100mg, vitamin E 14mg, vitamin K2 90μg。
The present embodiment alimentation composition is more beneficial for improving muscle decay, promotes muscle growth.
Embodiment 2
A kind of alimentation composition for improving the elderly's kinematic system function, is made up of following composition by weight：Whey egg
White 10g, whey protein peptide 0.5g, wheat protein peptide 0.5g, collagen peptide 10g, CPP 0.8g, leucine 2g,
Beta-hydroxy-Beta-methyl butyric acid 1g, calcium 0.7g, magnesium 0.3g, chick sternal cartilage 10g, chitosan oligosaccharide 0.3g, dimethyl sulfone 1.5g, turmeric
Plain 0.5g, vitamin B complex 42mg, μ g of vitamin D 8, vitamin C 100mg, vitamin E 14mg, vitamin K2 90μg。
The present embodiment alimentation composition is more beneficial for increasing bone density, improves osteoporosis.
Embodiment 3
A kind of alimentation composition for improving the elderly's kinematic system function, is made up of following composition by weight：Whey egg
White 10g, whey protein peptide 0.5g, wheat protein peptide 0.5g, collagen peptide 10g, CPP 0.2g, leucine 2g,
Beta-hydroxy-Beta-methyl butyric acid 1g, calcium 0.5g, magnesium 0.2g, chick sternal cartilage 20g, chitosan oligosaccharide 0.5g, dimethyl sulfone 2g, curcumin
0.8g, vitamin B complex 42mg, μ g of vitamin D 8, vitamin C 100mg, vitamin E 14mg, vitamin K2 90μg。
The present embodiment alimentation composition is more beneficial for promoting chondrocyte growth, accelerates bone matrix synthesis to promote joint
The reparation of cartilage and slow down articular cartilage degeneration, improve articular cartilage damage.
Embodiment 4
A kind of capsule for improving the elderly's kinematic system function, preparation method include：Example 1 improves the elderly's fortune
The alimentation composition 1000g of dynamic systemic-function, is made 0.5g/ grain capsules.
Embodiment 5
A kind of chewable tablets for improving the elderly's kinematic system function, preparation method include：Example 2 improves the elderly's fortune
The composition 1000g of dynamic systemic-function, after being mixed with the magnesium stearate of its weight 0.6%~1.0%, weight is pressed into tablet press machine
Measure the chewable tablets for 0.5g.
Embodiment 6
A kind of granule for improving the elderly's kinematic system function, preparation method include：Example 3 improves the elderly's fortune
The composition 1000g of dynamic systemic-function, after sieving mixing, add suitable quantity of water and prepare softwood, pelletized by one-step-granulating method, then
Dry, arrange, sieving after, it is canned enter bag, every bag of 15g.
Comparative example 1
A kind of alimentation composition, do not include lactalbumin with differing only in for embodiment 1.
Comparative example 2
A kind of alimentation composition, do not include vitamin k 2, vitamin D with differing only in for embodiment 2.
Comparative example 3
A kind of alimentation composition, do not include chick sternal cartilage with differing only in for embodiment 3.
Comparative example 4
A kind of alimentation composition, lactalbumin is replaced with to the soybean separation protein of equivalent with differing only in for embodiment 1
In vain.
Comparative example 5
Protein compositions are compounded, by lactalbumin 15g, whey protein peptide 0.7g, wheat protein peptide 0.7g, collagen
Peptide 10g, CPP 0.2g are formed.
Experimental example 1 improves the muscle attenuating experiment of kinematic system
1st, laboratory sample
It is prepared by the alimentation composition of improvement the elderly's kinematic system function prepared by embodiment 1, comparative example 1, comparative example 4
Alimentation composition, comparative example 5 compound protein compositions, lactalbumin (identical with the lactalbumin of embodiment 1).
2nd, experimental method
84 6-7 monthly age C57BL/6 mouse, are randomly divided into 7 groups, every group 12.Wherein 1 group is set to normal group, and in addition 6
Group mouse establishes muscle attenuation model in 42 days with dexamethasone subcutaneous administration 0.1ml/10g, successive administration.Corresponding to giving afterwards
Processing 60 days.Before modeling and before and after the processing, each group mouse carries out body composition, and (Echo MRITM toy body composition analysis instrument is purchased
From good biological share (China) Co., Ltd of remittance) detection, determine Lean mass.Each group mouse disposition is as follows：
Normal group：12, it is given only chow diet and water is fed；
Model group：12, it is given only chow diet and water is fed；
1 group of embodiment：12, fed except chow diet and water is given, the daily alimentation composition 7.8mg/ of gavage embodiment 1
G, continuous 60 days；
1 group of comparative example：12, fed except chow diet and water is given, the daily alimentation composition 5.3mg/ of gavage comparative example 1
G, continuous 60 days；
4 groups of comparative example：12, fed except chow diet and water is given, the daily alimentation composition 5.3mg/ of gavage comparative example 4
G, continuous 60 days；
5 groups of comparative example：12, except chow diet and water nursing is given, daily gavage comparative example 5 compounds protein compositions
4.5 mg/g, continuous 60 days；
Lactalbumin group：12, fed except chow diet and water is given, daily gavage lactalbumin 2.5mg/g, continuous 60
My god.
Note：Modeling principle：Glucocorticoid can promote the breaks down proteins in Various Tissues, as muscle, skin, lymph and
Bone tissue etc..It suppresses the synthesis of protein simultaneously, reduces assimilation, thus negative nitrogen balance occurs, makes muscle and lymph
Telatrophy, wound healing slowly etc..Clinical research confirmation, the patient through glucocorticoid treatment, its Lean mass substantially subtract
It is few.Dexamethasone is potency highest and a kind of most long hormone medicine of acting duration in glucocorticoid, therefore is utilized
Dexamethasone, which establishes muscle decay Syndrome Model, has the advantages that the cycle is shorter and positive effect.Dexamethasone is main to mouse
Failed by promoting protein degradation to induce muscle.
3rd, experimental result
It see the table below 1.
The each group mouse muscle content (g) of table 1
| Group | Before modeling | Before modeling post processing | After processing (gavage 60 days) |
| Normal group | 23.04±1.56 | 23.30±1.35 | 24.26±1.66 |
| Model group | 23.27±1.87 | 18.12±1.27* | 19.44±1.59 |
| 1 group of embodiment | 23.25±1.23 | 18.98±1.13* | 24.05±1.55## |
| 1 group of comparative example | 23.86±1.35 | 19.21±1.73* | 22.09±1.18# |
| 4 groups of comparative example | 23.47±1.32 | 19.13±1.27* | 22.79±1.42# |
| 5 groups of comparative example | 23.41±1.78 | 19.55±1.38* | 22.32±1.36# |
| Lactalbumin group | 23.20±1.40 | 19.34±1.31* | 21.33±1.28# |
Note：*Represent compared with normal group, P ＜ 0.05；**Represent compared with normal group, P ＜ 0.01.
#Represent compared with model control group, P ＜ 0.05；##Represent compared with model comparison, P ＜ 0.01.
As shown in Table 1, the Lean mass of normal group mouse is significantly higher than (P before the modeling post processing of model group and other groups
＜ 0.05)；Show that model is successfully established；Compared with model group, the Lean mass that 1 group of embodiment has pole significant difference (P ＜
0.01)；Compared with 1 group of comparative example, 4 groups of comparative example, 5 groups of comparative example, lactalbumin group, Lean mass also has non-1 group of embodiment
It is often significant to improve (P ＜ 0.05)；Comparative example 1, the Lean mass of 4 groups of mouse of comparative example are better than 5 groups of comparative example, lactalbumin
Group, but difference is not notable (P ＞ 0.05).
Above test result indicates that, in terms of the elderly's kinematic system muscle attenuation function is improved, one-component (such as breast
Albumin, whey protein peptide, wheat protein peptide) there is synergistic function, it is a kind of that its therapeutic effect is significantly better than exclusive use
Or several components.
Experimental example 2 improves the osteoporosis effect experiment of kinematic system
1st, laboratory sample
Nutrient combination prepared by the alimentation composition of improvement the elderly's kinematic system function prepared by embodiment 2, comparative example 2
Thing, calcium+VD compositions (being made up of calcium 0.7g, the μ g of vitamin D 8).
2nd, experimental method
60 months old rats of SD females unpregnancy 6, are randomly divided into 5 groups, every group 12.Wherein 1 group is set to normal group, and in addition 4
The Bilateral oophorectomy operation of group rats underwent, carries out osteoporosis modeling.Processing 60 days corresponding to giving for postoperative 5th day.Processing knot
Shu Hou, each group rat carry out femur midpoint Bone mineral density using X-RAY analyzers (carestream FXPRO).Each group is big
Mouse disposition is as follows：
Normal group：12, it is given only no soybean and its product feed and water is fed；
Model group：12, it is given only no soybean and its product feed and water is fed；
2 groups of embodiment：12, fed except no soybean and its product feed and water is given, the daily nutrition group of gavage embodiment 2
Compound 3.2mg/g, continuous 60 days；
2 groups of comparative example：12, fed except no soybean and its product feed and water is given, the daily nutrition group of gavage comparative example 2
Compound 3.2mg/g, continuous 60 days；
Calcium+VD groups：12, fed except no soybean and its product feed and water is given, daily gavage calcium+VD compositions (by
Calcium 0.7g, the μ g of vitamin D 8 are formed) 58 μ g/g, continuous 60 days.
Note：Modeling principle：Research is mostly using classical surgery excision bilateral ovaries modeling both at home and abroad at present, and the model is very
" the high conversion of function of osteoblast compensatory enhancing that osteoclast activity caused by good simulation goes out human body Estrin drop accelerates
The features such as type Bone m etabolism, it is the more commonly used animal model of current simulation osteoporosis.
3rd, experimental result
It see the table below 2.
The each group rat bone density measurement result (gm of table 23)
| Group | Bone density |
| Normal group | 7.40±0.53 |
| Model group | 5.01±0.29* |
| 2 groups of embodiment | 6.55±0.16## |
| 2 groups of comparative example | 5.91±0.12# |
| Calcium+VD groups | 5.83±0.17# |
Note：*Represent compared with normal group, P ＜ 0.05；**Represent compared with normal group, P ＜ 0.01.
#Represent compared with model control group, P ＜ 0.05；##Represent compared with model comparison, P ＜ 0.01.
As shown in Table 2, normal group bone density situation is significantly higher than model group (P ＜ 0.05)；Show that model is successfully established；With
Model group is compared, and the bone density situation of 2 groups of embodiment has pole significant difference (P ＜ 0.01)；2 groups of embodiment and 2 groups of comparative example, calcium
+ VD groups also have the improvement (P ＜ 0.05) of highly significant compared to bone density situation；It is excellent that 2 groups of rat bone densities of comparative example improve situation
In calcium+VD groups, but difference is not notable (P ＞ 0.05).
Above test result indicates that, improve the elderly's kinematic system osteoporosis function in terms of, 2 groups of treatments of embodiment
Significant effect is better than exclusive use wherein a few component.
Experimental example 3 improves the gonitis effect experiment of kinematic system
1st, laboratory sample
Nutrient combination prepared by the alimentation composition of improvement the elderly's kinematic system function prepared by embodiment 3, comparative example 3
Thing, Glucosamine+chondroitin sulfate compositions (being made up of Glucosamine 0.5g, chondroitin sulfate 0.2g).
2nd, experimental method
60 SD rats, it is randomly divided into 5 groups, every group 12.Wherein 1 group is set to normal group, in addition 4 groups of Rat Right knee joints
Row iodoacetic acid (1mg, 50 μ l) Injection in knuckle articular cavity, 1 times a week, continuous 4 times, carry out gonitis modeling.Before modeling starts
Each group rat gives corresponding processing within one week.30 days after the completion of modeling, put to death rat and extract right knee cartilage tissue specimen, use
Reverse transcription PCR (RT-PCR) method is to II Collagen Type VI in each group Rat Right knee cartilage, chondroproteoglycan (aggrecan)
Expression detected.Each group rat disposition is as follows：
Normal group：12, it is given only chow diet and water is fed
Model group：12, it is given only chow diet and water is fed
3 groups of embodiment：12, fed except no soybean and its product feed and water is given, the daily nutrition group of gavage embodiment 3
Compound 8mg/g, continuous 65 days
3 groups of comparative example：12, fed except no soybean and its product feed and water is given, the daily nutrition group of gavage comparative example 3
Compound 4.7mg/g, continuous 65 days
Glucosamine+chondroitin sulfate group：12, except no soybean and its product feed and water nursing is given, fill daily
Stomach Glucosamine+chondroitin sulfate compositions (is made up of) 250 μ g/g Glucosamine 0.5g, chondroitin sulfate 0.2g, even
It is continuous 65 days
Note：Osteoarthritis modeling principle：Injection in knuckle articular cavity is carried out from iodoacetic acid, changes articular cavity original
Stable state, MIA carry certain destruction for articular cartilage and surrounding synovial membrane are tough, plus adjoint inflammatory reaction, changed
The metabolism of cartilage and subchondral bone, the stabilization of intra-articular environment is destroyed, make articular chondrocyte apoptosis, cartilage wear.Meanwhile
The damage of intra-articular other structures is caused, periarticular proliferation of fibrous tissue forms spur, finally develops into osteoarthritis.
II Collagen Type VI, chondroproteoglycan are the important composition compositions of articular cartilage, and cartilage degeneration is important
Significant composition.
3rd, experimental result
Specific experiment result see the table below 3.
The each group rat Bones and joints index determining result of table 3
| Group | The expression (%) of II Collagen Type VI | The expression (%) of chondroproteoglycan |
| Normal group | 100.0 | 100.0 |
| Model group | 50.3±2.2** | 68.5±3.4** |
| 3 groups of embodiment | 84.5±3.1## | 92.3±4.7## |
| 3 groups of comparative example | 73.0±5.4## | 78.2±6.1## |
| Glucosamine+chondroitin sulfate group | 75.6±4.5## | 79.8±4.7## |
Note：*Represent compared with normal group, P ＜ 0.05；**Represent compared with normal group, P ＜ 0.01.
#Represent compared with model control group, P ＜ 0.05；##Represent compared with model comparison, P ＜ 0.01.
As shown in Table 3, the expression of the Collagen Type VI of normal group II and chondroproteoglycan is significantly higher than model group (P ＜ 0.01)；
Show that model is successfully established；
Compared with model group, the increase of II Collagen Type VI and chondroproteoglycan of 3 groups of embodiment has pole significant difference (P ＜
0.01)；
Compared with 3 groups of comparative example, Glucosamine+chondroitin sulfate group, II Collagen Type VI and chondroprotein gather 3 groups of embodiment
Sugared situation also has the improvement (P ＜ 0.05) of highly significant；
The expression of Glucosamine+Collagen Type VI of chondroitin sulfate group rat II and chondroproteoglycan is better than comparative example
3 groups, but difference is not notable (P ＞ 0.05).
Test result indicates that, in terms of the osteoarticular function of the elderly's kinematic system is improved, 3 groups of treatments of embodiment are imitated above
Fruit is significantly better than exclusive use wherein a few component.
The product stability of experimental example 4 (hot and humid acceleration)
1st, test specimen
Embodiment 1 is improved to the alimentation composition of the elderly's kinematic system function, is sub-packed according to a conventional method in packaging bag,
Every bag of 45g.
2nd, experimental method
With reference to like product, the shelf-life for estimating this product is at least 12 months.10 DEG C are often raised according to temperature, reaction increases
Add 1 times, shelf-life such as table 4 below of the initial guess under condition of different temperatures.
The accelerated test temperature of table 4 and shelf life corresponding table
| Temperature (DEG C) | Shelf life estimates (moon) |
| 20 | 12 |
| 30 | 6 |
| 40 | 3 |
| 50 | 1.5 |
| 60 | 0.75 (23 days) |
Above-mentioned test specimen is positioned over temperature 60 C, humidity 75% carries out hot and humid accelerated test, and in the 0th day and
The detection for carrying out index of correlation in 23rd day.Main purpose is the shelf-life of tentative prediction product and each nutrition in the range of the shelf-life
The stability of composition, physical stability, water activity, sensory modalities.
Nutritional ingredient detection includes main nutrient composition protein, fat and carbohydrate, and easily loses nutritional ingredient
Vitamin B complex, vitamin C and vitamin E.
Physical stability detects：The type Rapid Stabilities point of LUMiSizer 611 are utilized after product is reconstituted by a certain percentage
(Slope values represent the pace of change of liquid light transmittance in a period of time, integral light-transmitting for the detection of analyzer detection progress Slope values
It is plotted against time and can obtain slope of curve Slope values, its value is bigger, illustrates that the light transmittance of liquid changes faster, liquid stabilising
Property it is poorer, otherwise Slope values are smaller, liquid is more stable).
Water activity detects：The easy degree of microbial growth can be evaluated.Each microorganism grows in food
Breeding will have its minimum water activity requirement.If the water activity of food is less than this requirement, the growth and breeding of microorganism is just
It can be suppressed.When water activity is less than 0.6, most microorganisms can not grow.
Sensory modalities' evaluation includes：Color, smell, structural state, reconstitute the indexs such as liquid color, smell, dissolubility.
3rd, experimental result
The stability result of the nutritional ingredient of table 5
| Nutritional ingredient | 0th day | 23rd day |
| Protein g/100g | 61.5 | 60.2 |
| Fatty g/100g | 2.5 | 2.7 |
| Carbohydrate g/100g | 16.5 | 17.2 |
| Moisture, % | 2.55 | 2.78 |
| Vitamin B1 mg/100g | 25.0 | 27 |
| Vitamin B2 mg/100g | 26.2 | 28.1 |
| Vitamin B6 mg/100g | 25.8 | 26.5 |
| Vitamin C mg/100g | 202 | 195 |
| Vitamin E mg/100g | 27.0 | 25.8 |
The physical stability of table 6 and sensory modalities
As can be seen from the above results, the shelf-life of this product is more than December.The whether nutrition in the range of the shelf-life
Component content, product physical stability, or sensory modalities have stability features, can meet product quality requirement.
The crowd's test-meal of experimental example 5 is tested
1st, test specimen
Embodiment 1 is improved to the alimentation composition of the elderly's kinematic system function, is sub-packed according to a conventional method in packaging bag,
Every bag of 45g.
2nd, experimental method
Crowd's quantity：50 people；
The test-meal time/test-meal amount：60 days, daily 1 bag (45g)；
Crowd's inclusive criteria：>=60 years old, men and women was unlimited, had osteoporosis, knee cartilage degeneration, muscle decay wherein
One of health problem.
Osteoporosis criterion：Ultrasonic bone density instrument detects calcaneus's density, is diagnosed as osteoporosis；
Knee cartilage degeneration criterion：X pieces detection double knee joint, wherein one leg are diagnosed as knee cartilage and moved back
Change；
Muscle decay criterion：Meet following three conditions simultaneously：
1. grip reduces：Male ＜ 26kg, women ＜ 18kg；2. leg speed reduces, ＜ 0.8m/s；3. skeletal muscle mass drops
It is low：Male ＜ 7.0kg/m2, women ＜ 5.8kg/m2。
Before test-meal starts, subject carries out the detection of Lean mass and bone amount by body composition meter.After the completion of test-meal, by
Examination person fills in questionnaires, while carries out the detection of Lean mass and bone amount again.
There is the option of 5 and problem above as effective for " improving " in questionnaire.Specific questionnaire content such as table 7 below：
The crowd's test-meal questionnaire of table 7
Lean mass and bone amount, it is effective that numerical value, which increases above 10%,.
3rd, experimental result
The test-meal effect of table 8 counts
| Survey/n | Lean mass increase | Bone amount increase | |
| Efficiently individual quantity | 41 | 35 | 38 |
| Invalid number | 9 | 15 | 12 |
| It is efficient | 82% | 70% | 76% |
The effective percentage of test-meal 60 days is formulated described in embodiment it can be seen from data above 1 more than 70%, to the elderly
The kinematic system problems such as osteoporosis, knee cartilage are degenerated, muscle decay, which have, significantly improves effect.
Although above the present invention is described in detail with a general description of the specific embodiments,
On the basis of the present invention, it can be made some modifications or improvements, this will be apparent to those skilled in the art.Cause
This, these modifications or improvements, belong to the scope of protection of present invention without departing from theon the basis of the spirit of the present invention.
Claims (9)
1. a kind of alimentation composition for improving the elderly's kinematic system function, it is characterised in that by following by weight into packet
Into：Lactalbumin 10-15 parts, whey protein peptide 0.5-1 parts, wheat protein peptide 0.5-1 parts, collagen peptide 2-10 parts, junket egg
White phosphoeptide 0.05-0.15 parts, leucine 2-5 parts, beta-hydroxy-Beta-methyl butyric acid 0.5-3 parts, calcium 0.5-1 parts, magnesium 0.2-0.5
Part, chick sternal cartilage 5-20 parts, chitosan oligosaccharide 0.1-0.5 parts, dimethyl sulfone 0.5-2 parts, curcumin 0.1-1 parts, vitamin mixing
Thing 0.8-1.2 parts.
2. the alimentation composition according to claim 1 for improving the elderly's kinematic system function, it is characterised in that by following
Composition forms by weight：Lactalbumin 12-15 parts, whey protein peptide 0.5-0.8 parts, wheat protein peptide 0.5-0.8 parts, collagen
Protein peptides 3-10 parts, CPP 0.05-0.1 parts, leucine 2-4 parts, beta-hydroxy-Beta-methyl butyric acid 1-3 parts, calcium 0.5-
0.8 part, magnesium 0.2-0.4 parts, chick sternal cartilage 10-20 parts, chitosan oligosaccharide 0.2-0.5 parts, dimethyl sulfone 1-2 parts, curcumin 0.5-1
Part, vitamin mixtures 0.9-1.1 parts；
Preferably, it is made up of following composition by weight：Lactalbumin 14-15 parts, whey protein peptide 0.6-0.7 parts, wheat egg
White peptide 0.6-0.7 parts, collagen peptide 5-10 parts, CPP 0.05-0.8 parts, leucine 3-4 parts, beta-hydroxy-β-first
Base butyric acid 2-3 parts, calcium 0.5-0.6 parts, magnesium 0.2-0.3 parts, chick sternal cartilage 15-20 parts, chitosan oligosaccharide 0.3-0.5 parts, dimethyl
Sulfone 1.5-2 parts, curcumin 0.5-0.8 parts, vitamin mixtures 0.9-1.0 parts.
3. the alimentation composition according to claim 1 or 2 for improving the elderly's kinematic system function, it is characterised in that institute
State vitamin mixtures and contain vitamin B complex, vitamin D, vitamin C, vitamin E, vitamin K2。
4. the alimentation composition of improvement the elderly's kinematic system function according to claim any one of 1-3, its feature exist
In,
The content of each vitamin is in vitamin mixtures described in per 1g：Vitamin B complex 12-42mg, vitamin D 3-10 μ g, dimension
Raw plain C 30-100mg, vitamin E 5-15mg, vitamin K270-90μg；
Preferably, the content of each vitamin is in vitamin mixtures described in every 1g：Vitamin B complex 20-42mg, vitamin D 5-
10 μ g, vitamin C 50-100mg, vitamin E 10-15mg, vitamin K280-90μg；
It is further preferred that the content of each vitamin is in vitamin mixtures described in per 1g：Vitamin B complex 42mg, vitamin D
8 μ g, vitamin C 100mg, vitamin E 14mg, vitamin K2 90μg。
5. the alimentation composition according to claim 1 for improving the elderly's kinematic system function, it is characterised in that by following
Composition forms by weight：Lactalbumin 15g, whey protein peptide 0.7g, wheat protein peptide 0.7g, collagen peptide 10g, junket egg
White phosphoeptide 0.2g, leucine 4g, beta-hydroxy-Beta-methyl butyric acid 3g, calcium 0.5g, magnesium 0.2g, chick sternal cartilage 10g, chitosan oligosaccharide
0.3g, dimethyl sulfone 1.5g, curcumin 0.5g, vitamin B complex 42mg, μ g of vitamin D 8, vitamin C 100mg, vitamin E
14mg, vitamin K290μg；Or
It is made up of following composition by weight：Lactalbumin 10g, whey protein peptide 0.5g, wheat protein peptide 0.5g, collagen
Peptide 10g, CPP 0.8g, leucine 2g, beta-hydroxy-Beta-methyl butyric acid 1g, calcium 0.7g, magnesium 0.3g, chick sternal cartilage
10g, chitosan oligosaccharide 0.3g, dimethyl sulfone 1.5g, curcumin 0.5g, vitamin B complex 42mg, μ g of vitamin D 8, vitamin C
100mg, vitamin E 14mg, vitamin K290μg；Or
It is made up of following composition by weight：Lactalbumin 10g, whey protein peptide 0.5g, wheat protein peptide 0.5g, collagen
Peptide 10g, CPP 0.2g, leucine 2g, beta-hydroxy-Beta-methyl butyric acid 1g, calcium 0.5g, magnesium 0.2g, chick sternal cartilage
20g, chitosan oligosaccharide 0.5g, dimethyl sulfone 2g, curcumin 0.8g, vitamin B complex 42mg, μ g of vitamin D 8, vitamin C 100mg,
Vitamin E 14mg, vitamin K2 90μg。
6. the preparation method of any one of the claim 1-5 alimentation compositions for improving the elderly's kinematic system function, it is special
Sign is, including takes each raw material, mixing by proportioning.
7. the preparation containing any one of the claim 1-5 alimentation compositions for improving the elderly's kinematic system function；Enter one
Step ground, the preparation is also containing auxiliary material and/or additive used in field of food, field of health care food；Or the preparation also contains
There is pharmaceutically available carrier.
8. preparation according to claim 7, it is characterised in that it is tablet, capsule, granule, powder or pressed candy
Fruit.
9. any one of the claim 1-5 alimentation compositions for improving the elderly's kinematic system function or the institute of claim 7 or 8
State application of the preparation in food or health products or medicine is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710693890.2A CN107348522A (en) | 2017-08-14 | 2017-08-14 | A kind of alimentation composition for improving the elderly's kinematic system function and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710693890.2A CN107348522A (en) | 2017-08-14 | 2017-08-14 | A kind of alimentation composition for improving the elderly's kinematic system function and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107348522A true CN107348522A (en) | 2017-11-17 |
Family
ID=60286742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710693890.2A Pending CN107348522A (en) | 2017-08-14 | 2017-08-14 | A kind of alimentation composition for improving the elderly's kinematic system function and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107348522A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108157878A (en) * | 2018-01-09 | 2018-06-15 | 纽斯葆广赛（广东）生物科技股份有限公司 | A kind of high fine calcium fortification collagen jelly and preparation method thereof |
| WO2019101700A1 (en) * | 2017-11-21 | 2019-05-31 | Nestec S.A. | Compositions and methods using oleuropein or curcumin for muscle quality and/or muscle mass |
| CN110214947A (en) * | 2019-06-12 | 2019-09-10 | 宁波依萃健生物科技有限公司 | A kind of prevention and treatment osteoarthritis composition |
| CN112401240A (en) * | 2020-12-10 | 2021-02-26 | 泓博元生命科技（深圳）有限公司 | Mitochondrial sports nutritional compositions |
| CN115918914A (en) * | 2022-12-01 | 2023-04-07 | 宝健（北京）生物技术有限公司 | Oral nutritional supplement containing compound protein, preparation and application |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101248882A (en) * | 2008-03-28 | 2008-08-27 | 北京东方兴企食品工业技术有限公司 | Nutrition food product with promoting health of bones and bone arthrosis |
| CN102133395A (en) * | 2011-03-18 | 2011-07-27 | 上海海维生物科技有限公司 | Skeleton health-care product or medicinal composite and application thereof |
| CN103079415A (en) * | 2010-07-07 | 2013-05-01 | N.V.努特里西阿公司 | Nutritional composition for the stimulation of muscle protein synthesis |
| CN105363023A (en) * | 2015-11-11 | 2016-03-02 | 深圳太太药业有限公司 | Composition with effects of protecting joints and increasing bone mineral density and preparation method of composition |
| CN105520135A (en) * | 2015-12-20 | 2016-04-27 | 雷西云 | Healthy food with function of treating osteoporosis |
| CN105725190A (en) * | 2016-02-15 | 2016-07-06 | 北京东方兴企食品工业技术有限公司 | Functional nutrient food for improving joints |
| CN106072573A (en) * | 2016-07-05 | 2016-11-09 | 郑州和正生物科技有限公司 | A kind of it is applicable to the special dietary seafood that old aged muscle decay disease is edible |
| CN106213492A (en) * | 2016-07-22 | 2016-12-14 | 山东博奥克生物科技有限公司 | A kind of lifter motion function also increases health-oriented products and the preparation method of bone density |
-
2017
- 2017-08-14 CN CN201710693890.2A patent/CN107348522A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101248882A (en) * | 2008-03-28 | 2008-08-27 | 北京东方兴企食品工业技术有限公司 | Nutrition food product with promoting health of bones and bone arthrosis |
| CN103079415A (en) * | 2010-07-07 | 2013-05-01 | N.V.努特里西阿公司 | Nutritional composition for the stimulation of muscle protein synthesis |
| CN102133395A (en) * | 2011-03-18 | 2011-07-27 | 上海海维生物科技有限公司 | Skeleton health-care product or medicinal composite and application thereof |
| CN105363023A (en) * | 2015-11-11 | 2016-03-02 | 深圳太太药业有限公司 | Composition with effects of protecting joints and increasing bone mineral density and preparation method of composition |
| CN105520135A (en) * | 2015-12-20 | 2016-04-27 | 雷西云 | Healthy food with function of treating osteoporosis |
| CN105725190A (en) * | 2016-02-15 | 2016-07-06 | 北京东方兴企食品工业技术有限公司 | Functional nutrient food for improving joints |
| CN106072573A (en) * | 2016-07-05 | 2016-11-09 | 郑州和正生物科技有限公司 | A kind of it is applicable to the special dietary seafood that old aged muscle decay disease is edible |
| CN106213492A (en) * | 2016-07-22 | 2016-12-14 | 山东博奥克生物科技有限公司 | A kind of lifter motion function also increases health-oriented products and the preparation method of bone density |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019101700A1 (en) * | 2017-11-21 | 2019-05-31 | Nestec S.A. | Compositions and methods using oleuropein or curcumin for muscle quality and/or muscle mass |
| CN111315239A (en) * | 2017-11-21 | 2020-06-19 | 雀巢产品有限公司 | Compositions and methods for using oleuropein or curcumin for muscle mass and/or muscle mass |
| CN108157878A (en) * | 2018-01-09 | 2018-06-15 | 纽斯葆广赛（广东）生物科技股份有限公司 | A kind of high fine calcium fortification collagen jelly and preparation method thereof |
| CN110214947A (en) * | 2019-06-12 | 2019-09-10 | 宁波依萃健生物科技有限公司 | A kind of prevention and treatment osteoarthritis composition |
| CN112401240A (en) * | 2020-12-10 | 2021-02-26 | 泓博元生命科技（深圳）有限公司 | Mitochondrial sports nutritional compositions |
| CN115918914A (en) * | 2022-12-01 | 2023-04-07 | 宝健（北京）生物技术有限公司 | Oral nutritional supplement containing compound protein, preparation and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107348522A (en) | A kind of alimentation composition for improving the elderly's kinematic system function and preparation method thereof | |
| CN101248882B (en) | Nutrition food product with promoting health of bones and bone arthrosis | |
| Banerjee et al. | Effect of creatine monohydrate in improving cellular energetics and muscle strength in ambulatory Duchenne muscular dystrophy patients: a randomized, placebo-controlled 31P MRS study | |
| JP2020058351A (en) | Compositions for use in stimulating bone growth | |
| CN102647990A (en) | Methods of attenuating the loss of functional status | |
| AU2017270131A1 (en) | Nutritional composition for treating or preventing impaired mobility | |
| CN102781258A (en) | Nutritional compositions for modulating inflammation including exogenous vitamin K2 | |
| EA020252B1 (en) | Methods and compositions for the treatment of bone conditions | |
| JP2021502064A (en) | How to choose probiotics | |
| JP2007504182A (en) | Compositions and methods for promoting bone healing | |
| CN102753043A (en) | Nutritional compositions and methods for optimizing dietary acid-base potential | |
| Malyugina et al. | The Practicability of the Application of Vitamin D in Combination with Vitamin C for the Improvement of Bone Tissue Metabolism. | |
| Heymsfield et al. | Fiber supplementation of enteral formulas: effects on the bioavailability of major nutrients and gastrointestinal tolerance | |
| KR20100107468A (en) | Formulas comprising calcium, magnesium, zinc, and vitamine d3 for the prevention and amelioration of osteoporosis | |
| CN101669938B (en) | Nutrient composition for eliminating exercise-induced fatigue | |
| CN103889432A (en) | Agent for increasing amount of muscles | |
| TWI830696B (en) | Compositions for inhibiting muscle fiber degeneration | |
| CN101690591A (en) | Yak marrow polypeptide bone growing and height increasing tablets (powder) | |
| CN101692907A (en) | High-activity yak marrow bio-calcium compound capsule | |
| US20200030349A1 (en) | Physiologically active preparation comprising n-acetyl-glucosamine for the treatment of back pain | |
| CN108719998A (en) | A kind of oral diet supplement medicament for treating osteoarthritis | |
| Herminiati et al. | The effectivity of Difructose Anhydride III to increase absorption of calcium in the femur bone of calcium deficient rats | |
| JP2023518058A (en) | Compositions for enhancing urolithin production in human subjects | |
| OMI et al. | The effect of spiny lobster shell powder on bone metabolism in ovariectomized osteoporotic model rats | |
| CN106036387A (en) | Super chenopodium quinoa willd nutritional packet for promoting growth of children |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yang Yuexin Inventor after: He Mei Inventor after: Chen Chaoqing Inventor after: Wang Xuemin Inventor after: Zhang Yan Inventor after: Wu Minhui Inventor after: Han Lili Inventor before: Chen Chaoqing Inventor before: He Mei Inventor before: Wang Xuemin Inventor before: Zhang Yan Inventor before: Wu Minhui Inventor before: Han Lili |
|
| CB03 | Change of inventor or designer information |